Key result
OMACOR therapy significantly reduced fasting serum triglycerides by 29.46% compared to a 0.26% increase with placebo in Chinese patients with severe hypertriglyceridemia (p=0.0019).
Why the study?
The lipid-modifying potential of omega-3 polyunsaturated fatty acids in Chinese patients is under-researched.
Does highly purified ethyl esters of omega-3 polyunsaturated fatty acids reduce fasting serum triglycerides in Chinese adult patients with hypertriglyceridemia?
RCT
double-blind
randomized
Yes
Does highly purified ethyl esters of omega-3 polyunsaturated fatty acids reduce fasting serum triglycerides in Chinese adult patients with hypertriglyceridemia?
Absolute Event Rate: -29.46% vs 0.26%
p-value: p=0.0019
Omega-3 polyunsaturated fatty acid ethyl esters at 2-4 g/day significantly reduce fasting serum triglycerides in Chinese patients with hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Supports OMACOR 2–4 g/day for TG lowering in Chinese adults; extends Western RCT data to this population.
Qi et al. (2021) conducted an RCT in hypertriglyceridemia. OMACOR (OM3EE) vs. placebo was evaluated on percentage change in fasting serum triglycerides between baseline and the end of treatment in patients with severe hypertriglyceridemia (p=0.0019). OMACOR therapy significantly reduced fasting serum triglycerides by 29.46% compared to a 0.26% increase with placebo in Chinese patients with severe hypertriglyceridemia (p=0.0019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: